Engineering nanomedicines for improved melanoma therapy: progress and promises.
Engineering nanomedicines for improved melanoma therapy: progress and promises.
复制标题
DOI：
10.2217/nnm.10.117
复制
发表时间：
2010-11
期刊：
影响因子：
--
通讯作者：
Youan BB
中科院分区：
文献类型：
--
作者：
Bei D;Meng J;Youan BB
一旦转移，黑色素瘤仍然是最具侵袭性和病态的恶性肿瘤之一。此外，在过去的几十年里，晚期不可切除的黑色素瘤的总生存期一直表现出预后不良。低反应率和严重的副作用是基于化疗剂组合或免疫疗法与IL-2的标准疗法的特征。例如，包括达卡巴嗪、卡莫司汀、顺铂和他莫昔芬的化疗被称为“达特茅斯方案”，而CVD方案包括卡莫司汀、长春碱和达卡巴嗪。因此，迫切需要使用纳米科学和纳米技术作为替代策略来重新配制这些生物活性剂。本文概述了目前的设计和评估纳米医学进行，以解决这一未满足的医疗需求。所研究的纳米药物包括聚合物纳米颗粒、脂质体、聚合物囊泡、树枝状聚合物、立方体囊泡、囊泡和纳米金刚石。在这篇临床前文章中，纳米技术为有效治疗这种侵袭性和很大程度上耐药的疾病提供了希望。
Once metastatic, melanoma remains one of the most aggressive and morbid malignancies. Moreover, in past decades, the overall survival for advanced unresectable melanoma exhibited a constancy of poor prognosis. Low response rates and serious adverse effects have been characteristic of standard therapy based on a combination of chemotherapeutic agents or immunotherapy with IL-2. For example, the chemotherapy including dacarbazine, carmustin, cisplatin and tamoxifen is known as ‘Dartmouth regimen’ while the CVD regimen comprises carmustine, vinblastine and dacarbazine. Thus, there is an urgent and critical need to reformulate these bioactive agents using nanoscience and nanotechnology as alternative strategies. This article overviews current design and evaluation of nanomedicine undertaken to address this unmet medical need. The nanomedicines studied include polymeric nanoparticles, liposomes, polymersomes, dendrimers, cubosomes, niosomes and nanodiamonds. In this preclinical article, nanotechnology provides hope for effective treatment of this aggressive and largely treatment-resistant disease.